MAY 14, 2020 6:41 AM PDT

New Tech Has Its AI on Brain Tumors

WRITTEN BY: Tara Fernandez

 

A collaboration across 29 research and healthcare agencies is putting together the world’s largest brain tumor dataset to answer the question: could artificial intelligence (AI) detect brain tumors better than doctors can?

The project, led by Intel and Penn Medicine will receive $1.2 million in grant funding over 3 years from the National Institutes of Health (NIH). Diagnostic technologies driven by AI and machine learning have already proven their worth in accurately detecting skin, breast and lung cancers. Lessons learned from these platforms are informing strategies for the next wave of AI diagnostics. Fundamentally, the key to establishing a robust diagnostic platform, with minimal false positives and negatives, is to feed AI enough validated data for it to teach itself the difference between malignant and benign tissues.

Patient data, however, is extremely sensitive and subject to stringent privacy and security measures — making it a challenge for developers to access sufficiently large and robust datasets. To address this, the team is using a method known as federated learning, which uses encrypted data transfer and decentralized servers to securely channell patient data from all the participating centers.

 

 

Over 23,000 adults and 3,500 children in the United States will be diagnosed with a brain tumor this year. In brain cancer, masses of abnormal cells, which can be either cancerous or benign, begin to grow. Both can cause severe neurological conditions due to the build up of pressure on sensitive brain tissue. Headaches, blurred vision and memory loss are among some of the early symptoms of this cancer of the nervous system. Although in many cases, the early stages can be completely asymptomatic, with brain tumors being picked up by chance — for example, when a patient gets a scan for a traumatic head injury.

Advanced imaging techniques are allowing physicians to scan the brain with unprecedented clarity and are a source of rich, high-quality data from which to train AI. Rather than replacing human doctors, AI-assisted diagnostics could very well play a central role in physicians' toolbox, giving them the power of insights from big datasets to catch tumors in their patients earlier.


Source: Engaget.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 26, 2020
Clinical & Molecular DX
Nanoengineering Aids Bladder Cancer Detection
MAY 26, 2020
Nanoengineering Aids Bladder Cancer Detection
   
AUG 17, 2020
Cancer
Are Cancer Exosomes a Good Source of Biomarkers?
AUG 17, 2020
Are Cancer Exosomes a Good Source of Biomarkers?
One of cancer’s most aggravating qualities is its ability to control the microenvironment around it. This control ...
AUG 18, 2020
Clinical & Molecular DX
DIY COVID Tests Instead of Vaccines?
AUG 18, 2020
DIY COVID Tests Instead of Vaccines?
Routine, do-it-yourself COVID-19 testing could be just as good as a vaccine when it comes to stopping the transmission o ...
SEP 03, 2020
Cell & Molecular Biology
Diagnosing Non-Celiac Gluten Sensitivity
SEP 03, 2020
Diagnosing Non-Celiac Gluten Sensitivity
Many clinicians once thought that only celiac disease caused gluten intolerance. But some people without it report gastr ...
SEP 16, 2020
Cancer
Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?
SEP 16, 2020
Does Discontinuation of Immunotherapy Effect Final Results in Metastatic Melanoma?
The last decade has seen the emergence of several new therapies against cancer. For melanoma, checkpoint inhibitors have ...
SEP 21, 2020
Cancer
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
SEP 21, 2020
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
Cancer is an incredibly diverse disease. It has many types and even sub-types, with a vast range of characteristics. Som ...
Loading Comments...